Table 2B.
IDH-mutated LGGs: Cox regression analysis for the association of MPFS with preoperative clinical, imaging and molecular factors: EOR, grade III at first diagnosis, integrated diagnosis (astrocytoma), and previous treatment were significantly associated to MPFS
| HR | 95% CI | Pr(>|z|) | |
|---|---|---|---|
| EOR S vs P | 0.53 | 0.12–2.41 | 0.41 |
| EOR ST vs P | 0.01 | 0.00–0.09 | <0.01 |
| EOR T vs P | 0.25 | 0.05–1.17 | 0.08 |
| Grade III vs Grade II | 3.89 | 2.20–6.88 | <0.01 |
| Integr.diagn. Oligo vs Astro | 0.51 | 0.29–0.92 | 0.02 |
| Duration clinical history >6 vs <6 months | 1.03 | 0.54–1.96 | 0.94 |
| Previous Treat. yes vs no | 2.58 | 1.43–4.63 | <0.01 |
| Location T vs F | 0.84 | 0.34–2.11 | 0.72 |
| Location P vs F | 1.29 | 0.62–2.69 | 0.50 |
| Location Ins. vs F | 1.43 | 0.76–2.70 | 0.26 |
| Right vs Left | 0.44 | 0.17–1.10 | 0.08 |
| Volume mL | 1.00 | 0.99–1.00 | 0.16 |
| Dominant no vs yes | 1.42 | 0.55–3.68 | 0.47 |
| CC no vs yes | 0.63 | 0.32–1.24 | 0.18 |
S, Subtotal; P, Partial; ST, supratotal; T, Total; Integr.Diagn., integrated diagnosis; Oligo, oligodendroglioma; Astro, astrocytoma; Previous Treats., previous treatments; Location: T, temporal, F, frontal, P, parietal, Ins., insular. Dominant, dominance; CC, corpus callosum involvement.